Quinalizarin 

Quinalizarin is a protein kinase CK2 inhibitor with a K_i of 0.052 μM. Quinalizarin exhibits antifungal and anticancer activities. Quinalizarin induces ROS production, apoptotic signaling, mitochondrial pathway activation, cell cycle arrest, and cytotoxicity in cancer cells. Quinalizarin inhibits hyphal growth, biofilm formation, and mature biofilm integrity of Candida albicans. Quinalizarin can be used in research related to cancer and fungal infections^[1][2][3][4].

Quinalizarin (1-100 μM; 24 h) potently inhibits the viability of SW480 and HCT-116 colorectal cancer cells in a dose-dependent manner^[1].
Quinalizarin (10 μM; 3-24 h) reduces the protein expression levels of cyclin B1 and CDK1/2 in a time-dependent manner, and induces G₂/M phase cell cycle arrest in SW480 colon cancer cells^[1].
Quinalizarin (10 μM; 3-24 h) induces caspase-3-dependent apoptosis in SW480 colorectal cancer cells, which is characterized by upregulated expression of p-p53, Bad, activated caspase-3 and activated PARP, as well as downregulated expression of Bcl-2^[1].
Quinalizarin (10 μmol/L; 3-24 h) reduces the phosphorylation levels of Akt, ERK and STAT3, and increases the phosphorylation levels of JNK and p38 in SW480 colon cancer cells^[1].
Quinalizarin (5, 20 μM; 4-24 h) is cell-permeable and inhibits endogenous CK2 activity in HEK-293T and Jurkat cells^[2].
Quinalizarin (1-100 µM; 24 h) potently inhibits the viability of human lung cancer A549, NCI-H23 and NCI-H460 cells, with IC₅₀ values of 12.1, 20.24 and 27.94 µM, respectively, and exerts no significant cytotoxicity against normal liver QSG-7701 cells^[3].
Quinalizarin (12.1 µM; 0-24 h) induces time-dependent G₀/G₁ cell cycle arrest and apoptosis in human lung cancer A549 cells^[3].
Quinalizarin (12.1 µM; 0-24 h) regulates the Akt, MAPK, STAT3 and p53 signaling pathways in human lung cancer A549 cells, and promotes cell apoptosis by inhibiting the phosphorylation of Akt, ERK and STAT3 and activating the phosphorylation of JNK, p38 and p53^[3].
Quinalizarin (12.1 µM; 0-24 h) induces time-dependent intracellular ROS production in human lung cancer A549 cells^[3].
Quinalizarin (0.5-128 µg/mL; 24 h) exhibits antifungal activity against a variety of pathogenic yeast strains, including Fluconazole (HY-B0101)-resistant clinical Candida albicans isolates, with MIC values ranging from 0.5 to 128 µg/mL^[4].
Quinalizarin (2-4 µg/mL; 10-24 h) inhibits hyphal growth of Candida albicans ATCC 10231 in a concentration-dependent manner^[4].
Quinalizarin (8-80 µg/mL; 24 h) reduces the viability and biomass of preformed mature Candida albicans biofilms^[4].
Quinalizarin (2-16 µg/mL; 5 h) significantly increases intracellular ROS levels in Candida albicans cells^[4].
Quinalizarin (2-16 µg/mL; 5 h) can significantly dissipate the mitochondrial membrane potential of Candida albicans^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

272.21

C₁₄H₈O₆

81-61-8

Solid

Orange to red

O=C1C2=C(C(O)=CC=C2O)C(C3=CC=C(O)C(O)=C13)=O

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Meng LQ, et al. Quinalizarin Induces Apoptosis through Reactive Oxygen Species (ROS)-Mediated Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathways in Colorectal Cancer Cells. Med Sci Monit. 2018;24:3710-3719. Published 2018 Jun 3.  [Content Brief]

  [2]. Cozza G, et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J. 2009;421(3):387-395. Published 2009 Jul 15.  [Content Brief]

  [3]. Meng LQ, et al. Quinalizarin exerts an anti-tumour effect on lung cancer A549 cells by modulating the Akt, MAPK, STAT3 and p53 signalling pathways. Mol Med Rep. 2018;17(2):2626-2634.  [Content Brief]

  [4]. Janeczko M, et al. Quinalizarin as a potential antifungal drug for the treatment of Candida albicans fungal infection in cancer patients. Microbiol Spectr. 2024 Mar 5;12(3):e0365223.  [Content Brief]